Moving Stocks: Relypsa, Inc. (NASDAQ:RLYP), Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Boston Scientific Corporation (NYSE:BSX), Graco Inc. (NYSE:GGG), Freeport-McMoRan Inc. (NYSE:FCX)

Relypsa, Inc. (NASDAQ:RLYP) belongs to Healthcare sector. Its weekly performance is -0.46%. On last trading day company shares ended up $32.41. Relypsa, Inc. (NASDAQ:RLYP) distance from 50-day simple moving average (SMA50) is -4.25%. Relypsa Inc. (NASDAQ:RLYP) announced that one-year data from the Phase 2 AMETHYST-DN trial of Patiromer for Oral Suspension (Patiromer FOS) were published today in the Journal of the American Medical Association (JAMA). Results showed that patients with chronic kidney disease (CKD) and mild or moderate hyperkalemia who were treated with Patiromer FOS had statistically significant decreases in blood potassium levels from baseline at four weeks (p<0.001; primary endpoint).

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares moved up 6.04% in last trading session and ended the day at $8.08. PGNX Gross Margin is 99.10% and its return on assets is -17.10%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly performance is 27.24%. On 7 July, Progenics Pharma (NASDAQ: PGNX) announced details of its planned Phase 3 clinical trial for 1404, a developmental stage small molecule designed to help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA). Following recent End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), the design and key elements of a Phase 3 clinical trial for 1404 have been finalized.

On 14 July, Boston Scientific Corporation (NYSE:BSX) shares moved up 1.25% and was closed at $17.89. BSX EPS growth in last 5 year was 33.30%. Boston Scientific Corporation (NYSE:BSX) year to date (YTD) performance is 35.02%. On 9 July, Boston Scientific Corporation (NYSE:BSX) announced that Bronchial Thermoplasty (BT) delivered by the Alair™ System has received support from the American College of Allergy, Asthma and Immunology (ACAAI). BT is an outpatient procedure proven to reduce asthma attacks in adult patients with severe asthma.1 This endorsement demonstrates a growing clinical acceptance among allergists for this novel, procedure-based treatment option for severe asthma.

Graco Inc. (NYSE:GGG) ended the last trading day at $69.58. Company weekly volatility is calculated as 1.82% and price to cash ratio as 9.08. Graco Inc. (NYSE:GGG) showed a weekly performance of -2.00%. Graco Inc. (NYSE:GGG) announced that it will release its Second Quarter 2015 earnings after the New York Stock Exchange closes on Wednesday, July 22, 2015.

Freeport-McMoRan Inc. (NYSE:FCX) shares moved up 1.12% in last trading session and ended the day at $17.11. FCX Gross Margin is 6.10% and its return on assets is -7.10%. Freeport-McMoRan Inc. (NYSE:FCX) quarterly performance is -8.83%. Freeport-McMoRan Inc. (NYSE: FCX) announced it is changing the duties of two of its senior management team members, which reflect the growth and development of the managers, the mining giant said in a statement.

Leave a Reply

Your email address will not be published. Required fields are marked *